TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Relief of Tooth Sensitivity of an Experimental Mouthrinse Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females at least 18 years of age in good general and oral health without any known allergy to commercial dental products or cosmetics.~* Evidence of a personally signed and dated informed consent document indicating the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial.~* Willingness to use the assigned products according to instructions, availability for appointments, and likelihood of completing the clinical trial.~* The appropriate number and location of eligible teeth, based on protocol-defined standards.~* Adequate oral hygiene (i.e., brush teeth daily and exhibit no signs of oral neglect).~Exclusion Criteria:~* Any medical or dental history or condition, or use of any medication or drug, that per protocol or in the opinion of the investigator might compromise subject comfort or safety, or the analysis of study results.~* Volunteers who have been using any of the following within protocol-defined timeframes:~  * home-care bleaching, whitening products or professional bleaching treatment~ * desensitizing agents whether prescribed or over-the-counter~ * sensitivity toothpastes, mouthwash or oral care products used for the treatment of dentinal hypersensitivity~* Women who are pregnant, nursing or plan to become pregnant during the course of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 12027-027 (Type: EXPERIMENTAL): Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
- 310158077046 (Type: ACTIVE_COMPARATOR): Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
- 037000003212 (Type: PLACEBO_COMPARATOR): Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Trauma patient~2. Patient at the obvious age of equal or higher than 18 years of either sex~3. Major bleeding or occult bleeding with parameters of shock~4. Need for volume replacement therapy~5. Patient, who will be admitted to one of the participating hospitals~Exclusion Criteria:~1. Solely penetrating trauma~2. Solely head injury~3. In case of ongoing severe hemodynamic instability refractory to therapy (vasopressor, volume)~4. Patient with inevitable lethal course as evaluated by emergency physician~5. Need for CPR on the scene~6. Deep hypothermia (below 30°C)~7. Obviously pregnant women~8. Patient with known recent history of thromboembolic events within the last 6 months~9. Patient known to be on anticoagulant therapy~10. Patient with known refusal of a participation in this clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Human Fibrinogen Concentrate (Type: ACTIVE_COMPARATOR): Fibrinogen Concentrate will be administrated over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administrated over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate to severe chronic low back pain (lasting several hours daily) as their predominant pain condition for at least 3 months prior to screening,~* Subjects treated within the 14 days prior to screening with nonopioid therapy only, or with therapy including opioids at a dose of \<5 mg oxycodone (or equivalent) per day,~* Subjects whose low back pain is not adequately controlled with non-opioid analgesic medication and who the Investigator feels are appropriate candidates for around-the-clock opioid therapy~Exclusion Criteria:~* Subjects who had a surgical procedure directed towards the source of back pain within 6 months of screening or planned during the study conduct period,~* Subjects who are allergic to buprenorphine or who had a history of allergies to other opioids,~* Subjects who have allergies or other contraindications to transdermal delivery systems or patch adhesives.~Other protocol-specific inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-blind BTDS 10 or 20 (Type: EXPERIMENTAL): Buprenorphine transdermal system 10 or 20 mcg/h applied for 7-day wear
- Double-blind Placebo TDS (Type: PLACEBO_COMPARATOR): Placebo transdermal system to match BTDS patches, applied for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results.~Exclusion Criteria:~* A hyperparathyroidism

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Z-521 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to read, sign and date the informed consent and HIPAA documents~* Willing and able to comply with all study procedures~* Be at least 18 years of age~* Patient-reported history of dry eye in both eyes~* A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period~* Artificial tear use within the past 30 days~Exclusion Criteria:~* Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy~* Unwilling to avoid wearing contact lenses for 7 days prior to first visit and for the duration of the study~* Any blood donation or significant loss of blood within 56 days of Visit 1~* Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.~* Use of any prohibited medications at any time during the study unless otherwise specified~* Any significant illness that could interfere with study parameters~* History of laser assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to first visit, and/or any other ocular surgical procedure within 12 months prior to first visit; or any scheduled ocular surgical procedure during the study period.~* Known history of alcohol and/or drug abuse~* Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lifitegrast (Type: EXPERIMENTAL): Lifitegrast Ophthalmic Solution (5.0%)
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NESP Pediatric Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1 to 18 years of age~* ESRD receiving dialysis or CRI with eGFR less than 30 mL/min~* Baseline hemoglobin 9.5 - 12.5 g/dL and iron replete~* Stable rHuEPO therapy for 8 weeks~Exclusion Criteria:~* Scheduled for a living-related kidney transplant~* Uncontrolled blood pressure~* seizure activity~* Hyperparathyroidism~* Major surgery within 12 weeks or active inflammatory disease~* Currently receiving antibiotics~* Clinical evidence of malignancy~* Pregnant or breast-feeding

- Gender: None
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rHuEPO (Type: ACTIVE_COMPARATOR): None
- darbepoetin alfa (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Histologically confirmed non-small cell bronchogenic carcinoma~* Newly diagnosed or recurrent unresectable stage III or stage IV disease~* No mixed tumors with small cell anaplastic elements~* Measurable disease~* Must not have received any prior antineoplastic chemotherapy for lung cancer~* Age \> 18 years~* Able to perform activities of daily living with little or no assistance~* Adequate bone marrow, liver and kidney~* Understand the nature of this study and give written informed consent.~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Female patients who are pregnant or are lactating~* History of serious cardiovascular disease within the previous six months~* Serious active infection at the time of treatment~* Other serious underlying medical condition~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Chemotherapy-naïve patients with unresectable stage III/IV NSCLC received pemetrexed 500 mg/m2 IV and gemcitabine 1500 mg/m2 IV every 2 weeks for 8-12 cycles with restaging every 4 cycles. Patients also received supplemental folate/B12 therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects diagnosed with LCA or RP (with a mutation in either RPE65 or LRAT)~  * Subjects with LCA must be 5-65 years of age~ * Subjects with RP must be 18-65 years of age~* Subjects who have a best-corrected visual acuity of 3 letters or better (20/800 Snellen equivalent) or viable photoreceptors on OCT/FAF.~Exclusion Criteria:~* Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 60 days of Day 0.~* Subjects with any clinically important abnormal physical finding at Screening.~* Subjects who have taken any prescription or investigational oral retinoid medication (e.g., Accutane,® Soriatane®) within 6 months of Day 0 and subjects who did not tolerate their previous oral retinoid medication will be excluded regardless of the time of last exposure.~* Subjects with a history of diabetes or chronic hyperlipidemia, hepatitis, pancreatitis, or cirrhosis.~* Subjects who have taken any supplements containing ≥10,000 IU vitamin A within 60 days of screening

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Botox Cosmetic and the Young Patient With Glabellar Furrows

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Fitzpatrick Skin Types I-III~* Between 30 and 50 years of age~* At least moderate severity at maximum frown~Exclusion Criteria:~* Prior botulinum toxin treatment~* Any disorder (such as myasthenia gravis, Eaton-Lambert syndrome) or agent (such as aminoglycoside antibiotics) that might interfere with neuromuscular function~* Any other condition or situation that might put the subject at significant risk, confound the study results (such as significant pre-existing brow or eyelid ptosis)~* Allergy or sensitivity to any study component~* Participation in another clinical study within 30 days of the study start date~* Are planning other facial cosmetic procedures during the study period, or are pregnant, breastfeeding, or planning a pregnancy during the study.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Botox (Type: EXPERIMENTAL): Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be at least 18 years old.~* Patient must be diagnosed with depression and have had previous episodes of depression.~* Patient must sign informed consent.~Exclusion Criteria:~* Female and pregnant or breastfeeding.~* History of bipolar disorder, schizophrenia, or other psychotic disorders.~* Suffer from a serious medical illness (other than depression) or abnormal laboratory result that would require a change in medication, intervention, or hospitalization.~* Have been treated with a medication called monoamine oxidase inhibitor (MAOI) within 14 days of the start of the study, or potential need to use a MAOI within 5 days of finishing the study.~* Have taken an antidepressant called fluoxetine within 30 days of the start of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks
- B (Type: PLACEBO_COMPARATOR): duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quality Improvement and Personalization for Statins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: This was a clustered study. The investigators randomized five patient-aligned care teams (PACTS), intervened upon the physicians within each PACT, and evaluated the effect on individual patient visits.~* Eligible physicians were practicing PACT primary care physicians in the Ann Arbor VA Healthcare System.~* Eligible patients those who were seen in primary care during the period of analysis who were under 75 and who would be recommended a moderate-or-high-strength statin according to the VA/DoD guidelines, but were not on one at the time of the visit according to the electronic health record~Exclusion Criteria:~* Patient exclusion criteria included patients over the age of 75, or those who had an ICD-9 or ICD-10 codes for ESRD, muscle pain, pregnancy, or in-vitro fertilization in the 2 years prior to the study visit, those who were on moderate-or-high-strength statins, and those who were not eligible according to the guidelines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Primary Care Intervention Group (Type: EXPERIMENTAL): Primary care providers will receive a generated print-out of statin recommendations for patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant). Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the teamlets for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guidelines.
- Usual Care Group (Type: NO_INTERVENTION): PACT teams that were not randomized to the intervention will serve as a usual care group and will be expected to follow the VA guidelines and HEDIS measures as part of the VA national roll-out.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete